Background There are limited data on outcomes of moderate to severe coronavirus disease
2019 (COVID-19) among patients treated with remdesivir and dexamethasone in a real …

Background Remdesivir is approved by the US Food and Drug Administration for the
treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been …

Background Evidence is lacking about any additional benefits of introducing remdesivir on
top of dexamethasone, and the optimal timing of initiation. Methods In a territory-wide cohort …

Background Immunocompromised patients are at high risk of severe coronavirus disease
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …

Background The impact of remdesivir (RDV) on mortality rates in coronavirus disease 2019
(COVID-19) is controversial, and the mortality effect in subgroups of baseline disease …

Background Dexamethasone is standard of care for the treatment of patients with COVID-19
requiring oxygen. The objective is to assess the clinical benefit of adding remdesivir to …

Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-
care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a …

Purpose: To perform a systematic review and meta-analysis of randomized controlled trials
that examined remdesivir treatment for COVID-19. Materials and methods: A systematic …

Background There is an urgent need to understand the real-world effectiveness of
remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Background Remdesivir (RDV) improved clinical outcomes among hospitalized patients with
coronavirus disease 2019 (COVID-19) in randomized trials, but data from clinical practice …